An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia
MD Anderson Study Status
Cusatuzumab, Azacitidine, Venetoclax
The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Leukemia, Myeloid, Acute
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.